Risultati della ricerca - David N. Cook
- Mostra 1 - 7 risultati su 7
-
1
Molecular cloning and characterization of acrA and acrE genes of Escherichia coli di D Ma, David N. Cook, Marie Alberti, Ning G. Pon, Hiroshi Nikaido, John E. Hearst
Pubblicazione 1993Artigo -
2
-
3
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent<i>Clostridium difficile</i>Infection di Sahil Khanna, Darrell S. Pardi, Colleen Kelly, Colleen S. Kraft, Tanvi Dhere, Matthew R. Henn, Mary-Jane Lombardo, Marin Vulić, Toshiro K. Ohsumi, Jonathan Winkler, Christina Pindar, Barbara McGovern, Roger J. Pomerantz, John Auniņš, David N. Cook, Elizabeth Hohmann
Pubblicazione 2016Artigo -
4
Dosing a synbiotic of human milk oligosaccharides and B. infantis leads to reversible engraftment in healthy adult microbiomes without antibiotics di Julie E. Button, Chloe Autran, Abigail L. Reens, Casey M. Cosetta, Steven Smriga, M. Ericson, Jessica V. Pierce, David N. Cook, Martin L. Lee, Adam K. Sun, Amin M. Alousi, Andrew Y. Koh, David J. Rechtman, Robert R. Jenq, Gregory J. McKenzie
Pubblicazione 2022Artigo -
5
Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity di Dirk G. Brockstedt, Keith S. Bahjat, Martin Giedlin, Wei Liu, Mark K Leong, William Luckett, Yi Gao, Pamela Schnupf, Dilnawaz Kapadia, Grace Castro, Jie-Hui Lim, Adam Sampson-Johannes, Anat A. Herskovits, Adonis Stassinopoulos, H. G. Archie Bouwer, J Hearst, Daniel A. Portnoy, David N. Cook, Thomas W. Dubensky
Pubblicazione 2005Artigo -
6
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial di Barbara McGovern, Christopher B. Ford, Matthew R. Henn, Darrell S. Pardi, Sahil Khanna, Elizabeth Hohmann, Edward J. O’Brien, Christopher A. Desjardins, Patricia Bernardo, Jennifer R. Wortman, Mary-Jane Lombardo, Kevin Litcofsky, Jonathan Winkler, Christopher McChalicher, Sunny S. Li, Amelia D. Tomlinson, Madhumitha Nandakumar, David N. Cook, Roger J. Pomerantz, John Auniņš, Michele Trucksis
Pubblicazione 2020Artigo -
7
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis di Matthew R. Henn, Edward J. O’Brien, Liyang Diao, Brian G. Feagan, William J. Sandborn, Curtis Huttenhower, Jennifer R. Wortman, Barbara McGovern, Sherry Wang‐Weigand, David I. Lichter, Meghan Chafee, Christopher B. Ford, Patricia Bernardo, Peng Zhao, Sheri L. Simmons, Amelia D. Tomlinson, David N. Cook, Roger J. Pomerantz, Bharat Misra, John Auniņš, Michele Trucksis
Pubblicazione 2020Artigo
Strumenti per la ricerca:
Soggetti correlati
Biology
Microbiology
Genetics
Bacteria
Bioinformatics
Gene
Immunology
Medicine
Microbiome
Antibiotics
Clostridium difficile
Environmental health
Gastroenterology
Gut flora
Immune system
Immunity
Internal medicine
Listeria monocytogenes
Population
Virology
Virulence
Adverse effect
Alternative medicine
Amino acid
Antigen
Attenuated vaccine
Bifidobacterium
Bifidobacterium longum
Biochemistry
Butyrate